Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002430 · ClinicalTrials.gov registry record · NA
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
A NA study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- NA
- Development phase
- 220
- Enrollment target
NCT00002430 is a NA study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 220 participants.
The verdict
NCT00002430, a NA study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
Interventions
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Stavudine
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002430
The ClinicalTrials.gov registry entry for NCT00002430 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lamivudine is the first listed.
NCT00002430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002430 about?
NCT00002430 is a clinical study titled "A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations". The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
What is the current status of trial NCT00002430?
This trial is currently completed. It is a NA study. The enrollment target is 220 participants.
What interventions are being tested in trial NCT00002430?
The interventions under investigation include: Lamivudine (DRUG), Indinavir sulfate (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002430?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.